Home / Stocks / Tarsons Products Limited
TARSONS

Tarsons Products Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹303.7

Change

+5.5 (1.84%)

Open

₹299.7

Prev. Close

₹298.2

Day High

₹309.8

Day Low

₹294.15

Volume Analysis

Traded

27,285

Delivered

12,653

Delivery %

46.37%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (27.0%)

Weaknesses (2)

  • •Low return on equity (2.44%)
  • •Below-average fundamentals quality score (46/100)

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹326.6 ₹318.2 ₹310.95 ₹302.55 ₹295.3 ₹286.9 ₹279.65
Fibonacci ₹318.2 ₹312.22 ₹308.53 ₹302.55 ₹296.57 ₹292.88 ₹286.9
Camarilla ₹308.0 ₹306.57 ₹305.13 ₹302.55 ₹302.27 ₹300.83 ₹299.4

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+29.34%

1 Week

-2.54%

1 Month

+1.23%

3 Months

-11.96%

6 Months

+38.86%

1 Year

+37.48%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹84.87

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

1.01%

Net margin 1.51% × asset turnover 0.36x × equity multiplier 1.86x

Company Overview

Sector

Healthcare

Market Cap

₹1,678 Cr

P/E (TTM)

205.0

ROE

2.44%

Book Value

₹119.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Tarsons Products Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 46/100. The strongest factor is Financial Strength (81/100), while Institutional Ownership (11/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (27.0%); low return on equity (2.44%); below-average fundamentals quality score (46/100). FII holding has been falling.

TopFund Score — Fundamentals Quality

46/100 — Weak

Data confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

81

Growth

30

Valuation

25

Cash Flow

50

Corporate Governance

56

Momentum

72

Institutional Ownership

11

Business Quality

47

Risk & Volatility

48

Liquidity

27

From Screener.in

  • −Stock is trading at 2.65 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has low interest coverage ratio.
  • −Company has a low return on equity of 4.68% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Newspaper Publication of Financial Results for the quarter and half year ended September 30, 2026

Audio recording of 13 Nov 2026 investor conference call for Q2 FY27 results uploaded.

Investor Presentation for the quarter and half year ended September 30, 2026

Board approved unaudited standalone and consolidated results for quarter and half-year ended September 30, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Mar 2022 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 85 62 106 85 99 96 113 91 102 108 121 110 124
Expenses + 41 39 75 66 74 66 76 67 75 76 87 84 93
Operating Profit 44 23 30 19 25 30 37 25 27 32 34 26 31
OPM % 52.19% 37.03% 28.6% 22.12% 25.5% 30.98% 32.85% 27.04% 26.82% 29.21% 28.34% 23.58% 25.15%
Other Income + 3 3 3 3 8 1 4 3 6 7 7 6 4
Interest 0 3 4 4 5 5 5 5 5 6 6 6 7
Depreciation 7 10 12 11 14 17 20 20 22 25 29 27 28
Profit before tax 39 14 17 6 15 8 16 3 6 8 6 -1 1
Tax % 24.89% 26.72% 39.5% 36.39% 30.8% 34.66% 34.49% 41.25% 40.61% 32.93% 27.56% 9.09% 150.75%
Net Profit + 29 10 10 4 10 5 10 2 3 5 4 -1 0
EPS in Rs 6 2 2 1 2 1 2 0 1 1 1 0 0
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 26 — — — — 55 7 8 3 13 7 21 21

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2021 Mar 2022 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 229 301 296 392 423 463
Expenses + 125 148 196 282 304 340
Operating Profit 103 153 100 111 118 123
OPM % 45.0% 51.0% 34.0% 28.0% 28.0% 27.0%
Other Income + 5 8 11 16 23 24
Interest 3 4 10 20 23 25
Depreciation 14 22 40 62 97 109
Profit before tax 92 135 61 45 22 13
Tax % 25.0% 25.0% 30.0% 34.0% 35.0% —
Net Profit + 69 101 43 30 14 7
EPS in Rs 13 19 8 6 3 1
Dividend Payout % 0.0% 0.0% 25.0% 0.0% 0.0% —
Sales growth — 31 — 32 8 15

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2021 Mar 2022 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 244 479 602 620 624 622
Borrowings + 34 22 269 339 393 396
Other Liabilities + 18 33 90 111 158 150
Total Liabilities 296 544 972 1,080 1,186 1,179
Fixed Assets + 120 189 336 536 733 717
CWIP 22 32 267 233 159 168
Investments 0 0 0 0 0 0
Other Assets + 153 323 369 311 295 295
Total Assets 296 544 972 1,080 1,186 1,179
Equity Capital 0 11 11 11 11 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2021 Mar 2022 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 68 83 103 114 118
Cash from Investing Activity + -64 -138 -285 -145 -129
Cash from Financing Activity + -27 130 136 39 9
Net Cash Flow -23 75 -47 8 -2
Free Cash Flow 6 -48 -81 -37 -7
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 89 77 121 117 107

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 47.31% → 47.3%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 43.27% 44.36% 44.63% 44.45% 44.69% 42.89% 43.5% 46.79% 50.23% 51.65% 52.44% 51.53%
Promoters 47.31% 47.31% 47.31% 47.31% 47.31% 47.31% 47.31% 47.31% 47.3% 47.3% 47.3% 47.3%
FII 6.83% 8.16% 7.95% 8.04% 7.51% 9.53% 9.14% 5.82% 2.46% 0.87% 0.15% 0.55%
DII 2.6% 0.17% 0.11% 0.21% 0.51% 0.3% 0.04% 0.08% 0.0% 0.19% 0.1% 0.61%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Tarsons Products Limited (this stock) 1,678 205.0 2.65 2.44%
Krsnaa Diagnostics Ltd 1,661 16.9 1.6 10.9%
Fischer Medical Venture L 1,642 144.0 3.52 8.91%
Suraksha Diagnostic Ltd 1,780 42.6 6.45 14.2%
Ngl Fine Chem Limited 1,783 27.9 4.92 17.4%
Bharat Parenterals Ltd. 1,522 1227.0 4.59 -2.54%
Amrutajan Health Ltd 1,461 71.7 13.58 20.0%

Which Mutual Funds Hold Tarsons Products Limited?

Frequently Asked Questions about Tarsons Products Limited

Community Sentiment

What are other investors saying about Tarsons Products Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.